MaxCyte, Inc. (NASDAQ:MXCT) Shares Acquired by Verition Fund Management LLC

Verition Fund Management LLC increased its position in shares of MaxCyte, Inc. (NASDAQ:MXCT) by 39.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 21,335 shares of the company’s stock after acquiring an additional 6,045 shares during the period. Verition Fund Management LLC’s holdings in MaxCyte were worth $83,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of MXCT. Intech Investment Management LLC bought a new position in shares of MaxCyte during the 3rd quarter valued at about $51,000. China Universal Asset Management Co. Ltd. lifted its stake in MaxCyte by 64.6% during the third quarter. China Universal Asset Management Co. Ltd. now owns 20,212 shares of the company’s stock valued at $79,000 after purchasing an additional 7,930 shares during the last quarter. Creative Planning boosted its holdings in MaxCyte by 33.6% during the third quarter. Creative Planning now owns 28,652 shares of the company’s stock worth $111,000 after buying an additional 7,212 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in MaxCyte by 22.1% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 32,735 shares of the company’s stock worth $128,000 after buying an additional 5,927 shares during the last quarter. Finally, SG Americas Securities LLC increased its holdings in shares of MaxCyte by 84.5% in the third quarter. SG Americas Securities LLC now owns 37,969 shares of the company’s stock valued at $148,000 after buying an additional 17,385 shares in the last quarter. 68.81% of the stock is currently owned by institutional investors.

Insider Activity at MaxCyte

In other MaxCyte news, Director Stanley C. Erck sold 21,607 shares of MaxCyte stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $3.71, for a total transaction of $80,161.97. Following the transaction, the director now owns 269,118 shares of the company’s stock, valued at $998,427.78. The trade was a 7.43 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Over the last ninety days, insiders have sold 27,607 shares of company stock valued at $102,782. Company insiders own 3.00% of the company’s stock.

MaxCyte Stock Down 2.7 %

MXCT opened at $4.27 on Wednesday. The firm has a market cap of $451.30 million, a PE ratio of -12.56 and a beta of 1.37. The business has a fifty day simple moving average of $3.72 and a 200-day simple moving average of $4.05. MaxCyte, Inc. has a fifty-two week low of $3.16 and a fifty-two week high of $5.55.

MaxCyte (NASDAQ:MXCT) last announced its earnings results on Wednesday, November 6th. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.02. The company had revenue of $8.16 million during the quarter, compared to analysts’ expectations of $7.50 million. MaxCyte had a negative net margin of 78.36% and a negative return on equity of 16.00%. During the same period last year, the company posted ($0.11) earnings per share. On average, equities research analysts anticipate that MaxCyte, Inc. will post -0.42 EPS for the current fiscal year.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.